WO2010085648A3 - Methods for reducing radiation-induced tissue damage - Google Patents

Methods for reducing radiation-induced tissue damage Download PDF

Info

Publication number
WO2010085648A3
WO2010085648A3 PCT/US2010/021809 US2010021809W WO2010085648A3 WO 2010085648 A3 WO2010085648 A3 WO 2010085648A3 US 2010021809 W US2010021809 W US 2010021809W WO 2010085648 A3 WO2010085648 A3 WO 2010085648A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
tissue damage
tweak
induced tissue
reducing radiation
Prior art date
Application number
PCT/US2010/021809
Other languages
French (fr)
Other versions
WO2010085648A2 (en
Inventor
Burkly C. Linda
Taeko Dohi
Original Assignee
Linda Burkly C
Taeko Dohi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Linda Burkly C, Taeko Dohi filed Critical Linda Burkly C
Publication of WO2010085648A2 publication Critical patent/WO2010085648A2/en
Publication of WO2010085648A3 publication Critical patent/WO2010085648A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

Methods of preventing tissue damage induced by radiation therapy are provided. Disrupting the signaling of TNF family member TWEAK (TNF-like weak inducer of apoptosis) through its receptor Fn14 reduces levels of epithelial cell death and increases epithelial cell regeneration following radiation treatment in a mouse model of tissue injury by gamma-irradiation. Applications include use of an antagonist of TWEAK for preventing or reducing cell death that occurs as a result of radiation therapy.
PCT/US2010/021809 2009-01-23 2010-01-22 Methods for reducing radiation-induced tissue damage WO2010085648A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14704909P 2009-01-23 2009-01-23
US61/147,049 2009-01-23

Publications (2)

Publication Number Publication Date
WO2010085648A2 WO2010085648A2 (en) 2010-07-29
WO2010085648A3 true WO2010085648A3 (en) 2010-09-16

Family

ID=42356400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/021809 WO2010085648A2 (en) 2009-01-23 2010-01-22 Methods for reducing radiation-induced tissue damage

Country Status (1)

Country Link
WO (1) WO2010085648A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01007163A (en) 1999-01-15 2002-03-27 Biogen Inc Antagonists of tweak and of tweak receptor and their use to treat immunological disorders.
NZ548701A (en) 2002-04-09 2008-03-28 Biogen Idec Inc Methods for treating tweak-related conditions
EP2529619B1 (en) 2005-02-17 2015-09-23 Biogen MA Inc. Treating neurological disorders
AU2006244014B2 (en) 2005-05-10 2011-03-17 Biogen Ma Inc. Treating and evaluating inflammatory disorders
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020041876A1 (en) * 1999-12-20 2002-04-11 Wiley Steven R. TWEAK receptor
US20030039613A1 (en) * 1993-11-30 2003-02-27 Unger Evan C. Novel therapeutic delivery systems
US20080279853A1 (en) * 2005-05-27 2008-11-13 Biogen Idec Ma Inc. Treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030039613A1 (en) * 1993-11-30 2003-02-27 Unger Evan C. Novel therapeutic delivery systems
US20020041876A1 (en) * 1999-12-20 2002-04-11 Wiley Steven R. TWEAK receptor
US20080279853A1 (en) * 2005-05-27 2008-11-13 Biogen Idec Ma Inc. Treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DOHI ET AL.: "TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis", GASTROENTEROLOGY, vol. 136, no. 3, March 2009 (2009-03-01), pages 912 - 913, XP025997935, DOI: doi:10.1053/j.gastro.2008.11.017 *

Also Published As

Publication number Publication date
WO2010085648A2 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
MX2011012691A (en) Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye.
WO2010085648A3 (en) Methods for reducing radiation-induced tissue damage
TN2015000353A1 (en) Newcastle disease viruses and uses thereof
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
MX341025B (en) Combination therapy.
NZ631562A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
CL2013001247A1 (en) Method of treatment and / or prevention of oxidative stress, vascular stress and / or endothelial dysfunction in non-diabetic patients or in patients with diabetes such as type 1, latent adult autoimmune diabetes (dala) and type 2 diabetes, which includes administering linagliptin; Linagliptin compound, dpp-4 inhibitor.
WO2012068531A3 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
MX365242B (en) Use of cxcr4 antagonists.
GB201111485D0 (en) Drug composition and its use in therapy
MX2013007171A (en) Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms.
WO2013082440A3 (en) Methods of treating breast cancer with taxane therapy
NZ630170A (en) Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
BR112015008612A2 (en) Treatment Methods Using Adenovirus
MX2014000744A (en) Methods of treating pain.
WO2011143457A3 (en) Compositions and methods for treating or preventing atrial fibrillation
MY160556A (en) Neuregulin antagonists and use thereof in treating cancer
EP3517115A3 (en) Methods for treating hyperbilirubinemia with stannsoporfin
IN2014DN08385A (en)
WO2012006550A3 (en) Methods and compositions for treatment of lipogenic virus related conditions
PH12018501790A1 (en) Treatment of patients with homozygous familial hypercholesterolemia on lipid lowering therapy
EP2566502A4 (en) Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
MX2014014839A (en) Synergistic therapies of cannabidiol with hypothermia for neuroprotection.
EP2584900A4 (en) Combination therapy with cryosurgery and low dosage strength imiquimod to treat actinic keratosis
MY182801A (en) Compound for activating ampk and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10733904

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10733904

Country of ref document: EP

Kind code of ref document: A2